2013, Number 3
Pulmonary chronic graft versus host disease in allogeneic stem cell allografts. Diagnostic and therapeutic features
PDF size: 287.81 Kb.
ABSTRACTChronic graft versus host disease continous to be a major cause of both morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Clinical manifestations of pulmonary chronic graft versus host disease are characteristic, early diagnosis may improve clinical outcome. Here we discuss the current diagnosis and treatment of this deleterious complication.
Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the international bone marrow transplant registry and the European group for blood and marrow transplantation. Blood 2006; 108: 4288- 4290.
Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1261-1269.
Uderzo C, Pillon M, Corti P, Tridello G, Tana F, Zintl F, et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplant 2007; 39: 667-675.
Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12: 375-396.
Norman BC, Jacobsohn D, Williams KM, Au B, Au MA, Lee SJ, et al. Fluticasone, azithromycin, and montelukast (FAM) therapy in reducing steroid exposure in bronchiolitis obliterans syndrome after allogenic hematopoetic stem cell transplant (HCT)-a case series of 8 patients. Biol Blood Marrow Transplant 2010;16:S308.